NANO4 technology is extremely flexible and easily adapted to a range of applications where specific DNA or RNA sequence is critical, such as detection of human pathogen or selected cancers and other genetic diseases.
NANO4 platform is extremely flexible and easily adapted to a range of
applications where specific DNA or RNA sequence is critical, such as
detection of human pathogens (validation ongoing for M. tuberculosis,
Zika), selected cancers and other genetic diseases.
Pipeline
| R&D | Design | Development | Clinical Validation |
NANO4 CML forChronic myeloid leukemia (CML)
Chronic myeloid leukemia (CML) is a clonal bone marrow stem cell disease with an annual incidence of 1–2 new cases per 100,000 adults and accounting for approximately 15% of leukemia cases. The Philadelphia chromosome (Ph), a reciprocal translocation of the long arms of chromosomes 9 and 22, t(9;22), is found in more than 90% patients with CML, 15–25% of patients with acute lymphoblastic leukemia (ALL), and 1 % of newly diagnosed adults with acute myeloid leukemia (AML).
The vast majority of patients with CML (∼95 %) express either e13a2 or e14a2 mRNAs. NANO4 CML provides a fast, affordable and sensitive screening of CML
NANO4 CML - reads mRNA directly with a colorimetric output which does not need either retrotranscription or amplification. Most diagnostic assays require a cumbersome application of retrotranscription and RT-qPCR which takes more than 5 hours to provide a result.NANO4 CML gives a fast, decentralized, and affordable result for this malignancy.
NANO4 CML has recently completed validation studies at key Oncology Hospitals and is currently filing for CE-IVD registration. The commercial launch is forecasted in 2022.
If you would like to distribute this product, please message us using the contact page.